As reported by the PharmaTimes, The National Institute for Health and Clinical Excellence (NICE) has rejected Roche’s Avastin drug in the treatment of metatastic breast cancer due to doubts about efficiency.
According to NICE, whilst the clinical trial data indicated that Avastin could dlow the growth and spread of the tumour, it only extended patient survival by a maximum of seven weeks.
In addition, Andrew Dillon, the chief executive of NICE, stated that there was little evidence that Avastin “can give patients a better quality of life than paclitaxel or docetaxel”. Given these uncertainties, NICE ruled that, at more than £3,000 per patient per month, the drug is simply too expensive “for the limited and uncertain benefit it may offer patients”.
In response, Roche said it would respond to the consultation document and “plans to work closely with the Government to explore all possible avenues of making Avastin available to patients in the UK”.
Looking for a job in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.